Tech Company Financing Transactions
Zetagen Therapeutics Funding Round
On 8/11/2023, Zetagen Therapeutics secured $9.8 million in Series B funding from Consolidated Investment Group and New York Ventures.
Transaction Overview
Company Name
Announced On
8/11/2023
Transaction Type
Venture Equity
Amount
$9,790,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to support the progression of its R&D efforts of additional oncological pipeline assets as well as ancillary osteologic treatments. The Series B financing will support the advancement of its lead pipeline asset ZetaMet� which is currently in Phase 2a clinical trials for the treatment of metastatic breast cancer bone lesions as part of advanced stage cancer therapy. In addition to ZetaMet�, the funding will be used for the development of ZetaMAST� for the treatment of metastatic lesions to soft tissue organs, as well as other oncologic and osteologic pipeline assets. The company will also add new talent to support these advancing programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
841 East Fayette Street 1100
Syracuse, NY 13210
USA
Syracuse, NY 13210
USA
Phone
Undisclosed
Website
Email Address
Overview
Founded in 2015, Zetagen is a private, clinical-stage, biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions. Our multi-patented, ZetaMet� technology is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. Zetagen exclusively-licensed the platform technology from the State University of New York in 2016.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joe Loy
Chief Financial Officer
Jess Pletka
Chief Scientific Officer
Bryan Margulies
Browse more venture capital transactions:
Prev: 8/11/2023: Quility venture capital transaction
Next: 8/11/2023: Braid venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs